Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAP Study: Adalimumab and Methotrexate in Psoriasis
NCT03217734Phase 3Completed
- Sponsor
- Jeffrey J Crowley
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing ADA + Placebo with ADA + MTX (2 arms). Primary endpoint: Psoriasis Area and Severity Index Change at 16 weeks. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03217734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217734.